With the evolution of scalability of peripheral blood protein glycosylation, research has expanded for new biomarkers.
Klaus Lindpaintner
Advertisement
Klaus Lindpaintner, MD, MPH is chief scientific officer and distinguished scientist at InterVenn BioSciences.
Articles by Klaus Lindpaintner
Advertisement
Latest Updated Articles
- Using Novel Biomarkers to Facilitate AI-Driven Glycoproteomics
Published: November 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
2
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
3
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
4
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
5
